Kenvue, Inc. (KVUE)
NYSE:KVUE
Want to see KVUE full AI Analyst Report?
KVUE Stock Chart & Stats
$17.61
-$0.04(-0.19%)
At close: 4:00 PM EST
$17.61
-$0.04(-0.19%)
Day’s Range― - ―
52-Week Range$14.02 - $22.87
Previous CloseN/A
Volume2.33M
Average Volume (3M)20.90M
Market Cap
$34.83B
Enterprise Value$40.76B
Total Cash (Recent Filing)$1.07B
Total Debt (Recent Filing)$8.66B
Price to Earnings (P/E)21.4
Beta0.02
Next Earnings
Aug 12, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend Yield4.85%
Share Statistics
EPS (TTM)0.85
Shares Outstanding1,920,008,700
10 Day Avg. Volume20,513,848
30 Day Avg. Volume20,896,349
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.06
Price to Sales (P/S)2.18
P/FCF Ratio19.14
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue2.67
Enterprise Value/Gross Profit4.57
Enterprise Value/Ebitda12.86
Forecast
1Y Price Target
$18.80Price Target Upside6.76% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)1.19
Revenue Forecast (FY)$15.63B
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent, improving free cash flow (TTM ~$1.82B; ~83% conversion) indicates the business converts earnings to cash effectively. Durable FCF supports reinvestment, dividend coverage and debt reduction, giving the company strategic flexibility over multiple quarters.
Margin ResilienceHigh gross margins (~58%) and a recovered TTM net margin (~10.6%) reflect structural pricing power in branded consumer health and efficient manufacturing. Sustained margin levels provide a durable earnings cushion that helps fund marketing, R&D and brand investment without eroding profitability.
Diversified Brand PortfolioA broad portfolio spanning OTC medicines, skin health and essential personal care reduces dependence on any single category or channel. Brand recognition, retail shelf presence and multi-channel distribution create durable demand and resilience through consumer cycles.
Bears Say
Low Revenue GrowthTop‑line expansion is modest and effectively flat over recent years, limiting organic upside from core markets. Low growth forces management to rely on margin improvements, mix shifts or new product success to drive material earnings gains, which is riskier over time.
Elevated LeverageA debt-to-equity near 0.82 signals moderate-to-elevated leverage that reduces financial flexibility. Higher indebtedness increases sensitivity to interest rates, limits capacity for large M&A or aggressive capital returns, and raises refinancing risk over the medium term.
Earnings & Cash Flow VolatilityHistorical swings in margins and cash flow weaken predictability of free cash generation and complicate long‑range planning. Variable earnings increase the risk that dividends, reinvestment or debt reduction could be pressured during adverse cycles or unexpected cost shocks.
Kenvue, Inc. News
KVUE FAQ
What was Kenvue, Inc.’s price range in the past 12 months?
Kenvue, Inc. lowest stock price was $14.02 and its highest was $22.87 in the past 12 months.
What is Kenvue, Inc.’s market cap?
Kenvue, Inc.’s market cap is $34.83B.
When is Kenvue, Inc.’s upcoming earnings report date?
Kenvue, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 58 days.
How were Kenvue, Inc.’s earnings last quarter?
Kenvue, Inc. released its earnings results on May 07, 2026. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.262 by $0.058.
Is Kenvue, Inc. overvalued?
According to Wall Street analysts Kenvue, Inc.’s price is currently Undervalued.
Does Kenvue, Inc. pay dividends?
Kenvue, Inc. pays a Quarterly dividend of $0.207 which represents an annual dividend yield of 4.85%. See more information on Kenvue, Inc. dividends here
What is Kenvue, Inc.’s EPS estimate?
Kenvue, Inc.’s EPS estimate is 0.32.
How many shares outstanding does Kenvue, Inc. have?
Kenvue, Inc. has 1,920,008,700 shares outstanding.
What happened to Kenvue, Inc.’s price movement after its last earnings report?
Kenvue, Inc. reported an EPS of $0.32 in its last earnings report, beating expectations of $0.262. Following the earnings report the stock price went up 0.223%.
Which hedge fund is a major shareholder of Kenvue, Inc.?
Currently, no hedge funds are holding shares in KVUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kenvue, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$18.80 (6.76% Upside)
$18.80 (6.76% Upside)
Blogger Sentiment
Bullish
KVUE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 19.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $746.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.87%
12-Months-Change
Fundamentals
Return on Equity
15.18%
Trailing 12-Months
Asset Growth
2.27%
Trailing 12-Months
Company Description
Kenvue, Inc.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
KVUE Revenue Breakdown
42.17% Self Care
27.20% Skin Health and Beauty
30.63% Essential Health
KVUE Stock 12 Month Forecast
Average Price Target
$18.80
▲(6.76% Upside)
Technical Analysis
Ownership Overview
1.45% Insiders
23.73% Mutual Funds
19.65% Other Institutional Investors
24.60% Public Companies and Individual Investors